News
FDA explains dabigatran dose approval
The medical community was surprised when the Food and Drug Administration (FDA) approved the higher dose of dabigatran and not the lower dose last...
News
Dabigatran also recommended to treat AF
The new guidelines also included patients with atrial fibrillation with risk factors for stroke or blood clotting who do not have a prosthetic...
News
FDA warns of possible link between breast implants and ALCL
People with breast implants “may have a very small but significant risk of ALCL in the scar capsule adjacent to the implant,” according to the...
News
Dabigatran: lower hemorrhage risk than warfarin
A recent analysis of previous data found that while warfarin and dabigatran are comparable at preventing stroke in patients with atrial...
News
Treatment of CML continues to progress
Dr O’Brien listed standard-dose imatinib, high-dose imatinib, imatinib-based combinations, second generation tyrosine kinase inhibitors (TKIs) and...
News
FDA approves dabigatran for AF patients
The US Food and Drug Administration (FDA) has approved dabigatran etexilate (Pradaxa) to prevent strokes and thrombosis in patients with atrial...
News
Researchers reveal structure of CXCR4
A team of researchers has uncovered the structure of a cell surface receptor, CXCR4, which guides blood and immune cell movement throughout the...
News
FDA panel recommends dabigatran: 9-0
The decision was based on the randomized, noninferiority RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial of 18,000...
News
Second-line CML drugs prove better than first
Nilotinib and dasatinib, currently approved for the treatment of drug-resistant chronic myeloid leukemia (CML), provide quicker and better...
News
Denileukin diftitox has significant, durable responses in CTCL
The recombinant fusion protein denileukin diftitox (DD) produced a significant and durable overall response rate at 2 dose levels as compared to...
News
Phase 3 trial of pixantrone leaves FDA uneasy
The drug is intended to treat non-Hodgkin’s lymphoma (NHL) that has resisted at least 2 other treatments. Among multiple concerns, the trial only...
News
Dabigatran comparable to warfarin for acute VTE
NEW ORLEANS—The direct thrombin inhibitor dabigatran etexilate is a safe, effective anticoagulant that, unlike warfarin, does not require routine...
News
Panobinostat shows promise in refractory Hodgkin lymphoma
New York, NY —Growing evidence suggests that the potent pan-deacetylase inhibitor panobinostat (LBH589) shows promising clinical activity in...
News
Agent shows promise in acute leukemias
Delivering drugs in combination requires a certain balance, a balance that ensures the drugs act synergistically. And researchers say they have...